iPSCs : Recent Clinical Insights & Progress

iPSCs : Recent Clinical Insights & Progress

12 – 13 Nov 2026 | Paris, France

Register
Register
Register

iPSCs : Recent Clinical Insights & Progress

SPEAKERS

Prof. Dan S. Kaufman

Professor, Department of Medicine
Co-director of Sanford Stem Cell Institute
San Diego, USA
Endowed Chair Director,
Cell Therapy Program
Sanford Advanced Therapy Center, USA

Prof. Ali Turhan

Professor of Hematology School of Medicine
Paris Saclay University, France
Director of Clinical iPSC Program at CiTHERA/ INSERM U1210, France
Co-founder iPSirius

Prof. Frank Griscelli

Professor of Biotherapy
Paris Cité University, and Institut Gustave Roussy, France
Director of INSERM U1310, France
Co-Founder of iPSirius

Dr. Naosuke Nakamura

Assistant Professor
CiRa Foundation, Japan

Prof. Haruhisa Inoue

Assistance Director
Center for iPS Cell Research and Application (CiRA)
Kyoto University, Japan
Representative Director of the Japan Disease Stem Cell Society

Prof. Keiichi Fukuda

Chief Executive Officer
Representative Director of the Board,
Heartseed Inc., Tokyo, Japan

Prof. Ronald Li

Founder & CEO of
NovoHeart, Hong Kong
Medera, Boston USA

Prof Jung-Hyun Kim

Professor at Ajou University College of Pharmacy, Korea
Former Director of the Korea National Stem Cell Bank at the Korea National Institute of Health(KNIH)

Prof. Ji Hyeon Ju

Professor of Rheumatology, The Catholic University of Korea
CEO of YiPSCELL
Director of the Clinical Academic Committee of the Korea Society of Stem Cell Research (KSSCR)

Prof. Jihwan Song

Professor, Department of Biomedical Science,
CHA University,
Founder & CEO of iPS Bio Inc., South Korea

Dr. Anselme L. Perrier

Research Director at INSERM
Group leader at the CEA/CNRS U9199  Laboratory of Neurodegenerative Diseases, MIRCEN Infrastructure, France

Prof. Christelle Monville

Professor,
University of Evry
Team Leader at
I-Stem INSERM U861, France

Dr. Peter Andersen

Chief Research & Development Officer at
Treefrog Therapeutics, France

Dr Alex Ng

Co-founder & Chief Innovation Officer of
GC Therapeutics, USA

Dr. Boris Greber

Managing Director and Head of R&D
Catalent, Germany

Dr Alex Zhang

Chief Scientific Officer of
Zephyrm Biotechnologies, China

Prof. Anna Veiga

Director of the Barcelona Stem Cell Bank
Group leader at Pluripotent Stem Cell Therapy research group at the Regenerative Medicine Program (REGENBELL) at Institut d’ Investigació Biomèdica de Bellvitge (IDIBELL), Spain

Prof. Annelise Bennaceur Griscelli

Professor Hematology
School of Medicine
Paris Saclay University,
Director of CiTHERA, the Center for iPS Cell Therapies
Coordinator of The National iPSC Infrastructure INGESTEM,
Co-Founder of iPSirius

Prof. Anna Falk

Professor Stem Cell Center, Lund University, Sweden
Director of the Lund University ATMP Centre
Director of the PreGMP facility
CSO at CCRM Nordic, Sweden

Prof. Andras Nagy

Professor at
Institute of Medical Science
University of Toronto, Canada
Professor at
Australian Regenerative Medicine Institute,
Monash University, Australia

Prof. Hongkui Deng

Boya Chair Professor of Cell Biology,
Peking University Health Science Center
School of Basic Medical Sciences
Director of Peking University Stem Cell Research Center, China

Dr. Marcelo Rivolta

Professor of Sensory Stem Cell Biology
University of Sheffield, UK
Founder & CSO
RINRI Therapeutics, UK

Dr. Glyn Stacey

Professor at the Universities of Bedfordshire and Suffolk,UK
Institute of Stem Cell and Regeneration, CAS, Beijing, China

AGENDA

📅 Day 1 – November 12, 2026

08:30 – 09:15
Registration & Welcome Coffee
09:15 – 09:30
Welcome Address – Prof. A. Bennaceur Griscelli
09:30 – 09:45

Induced Pluripotent Stem Cells: Mapping the drug pipeline landscape and trends

MabDesign, France

Session I – iPSC and Cancer Therapy & Models

09:50 – 10:25

Keynote Conference: IPSC-based NK-Cell Therapies in Cancer

Dan Kaufman, UCSD, San Diego, USA

10:30 – 10:55

iPSC-based Cancer Organoid Models

Ali Turhan, Inserm, University Paris Saclay, France

10:55 – 11:30 Coffee Break
11:30 – 12:55

Early Clinical Developments

11:30 – 11:55

New paradigm for iPSC-based Cancer Vaccines

Frank Griscelli, Inserm, University Paris Saclay, Institut Gustave Roussy, IPSirius, France
11:55 – 12:15

Clinical-Grade iPS Cell Stock: A Decade of Progress, Current Status, and Future Challenges

Naosuke Nakamura, CiRA Foundation, Japan
12:15 – 12:35

Mechanistic Analysis and Drug Discovery in Neurodegenerative Diseases Using Patient-Derived Stem Cells

Haruhisa Inoue, CiRA Foundation, Japan
12:35 – 12:55
4 Short talks in Cancer
13:00 – 14:00 Lunch & Sponsor Booth Visits

Session II – iPSCs and Regenerative Medicine

14:00 – 14:45

Keynote Conference: Clinical Trials using Heart Spheroids derived from iPSC

Keiichi Fukuda, HeartSeed, Japan

14:45 – 15:30

Keynote Conference: Mini-Heart Tech Platform in Cardiology

Ronald Li, NovoHeart, Hong Kong

15:30 – 15:45

Key considerations for the development of hPSC-based cell therapies

Jung-Hyun Kim, College of Pharmacy, Ajou University, South Korea
15:45 – 16:00

Clinical Translation of an iPSC-Derived 3D Chondrospheroid Therapy for Osteoarthritis: First-in-Human Experience with MIUChon™

Ji Hyeon Ju, The Catholic University of Korea, YiPSCELL, South Korea
16:00 – 16:30 Coffee Break & Poster Session
16:30 – 17:30

iPSC-Based Therapies in Neurology & Ophthalmology

16:30 – 16:50

iPSC-derived Huntington Therapies

Jihwan Song, CHA Stem Cell Institute Seoul, South Korea
16:50 – 17:10

iPSC-based Huntington Models

Anselme Perrier, Inserm CEA, France
17:10 – 17:30

Pluripotent Stem Cell-Based Retinal Cell Therapies

Christelle Monville, University Evry, I-STEM, France
17:10 – 17:30

iPSC-Derived Preclinical Research in Parkinson's Disease (tbc)

Peter Andersen, Treefrog Therapeutics, France
End of Day 1

📅 Day 2 – November 13, 2026

Session III – Novel Approaches in iPSC Manufacturing and Differentiation

09:00 – 09:45

Keynote Conference: Driving iPSC Fate Through Direct Nuclear Reprogramming

Alex Ng, GC Therapeutics, USA

09:45 - 10:45

Safety, Consistency & Manufacturing

10:05 – 10:25

Manufacturing iPSC-Derived NK Cells

Boris Greber, Catalent, Germany
10:25 – 10:45

ESC-based MSC manufacturing in clinical trials

Yu Alex Zhang, Zephyrim Biotechnologies, Beijing, China
10:45 – 11:15 Coffee Break
11:15 – 12:00

European cGMP iPSC Landscape

11:15 – 11:30

HaploiPSC Program in Europe

Anna Veiga, Institut d’Investigació Biomèdica de Bellvitge. IDIBELL, Spain
11:30 – 11:45

Comprehensive Genomic Landscape of cGMP iPSC lines

Annelise Bennaceur-Griscelli, Inserm, University Paris Saclay, CiTHERA, France
11:45 – 12:00

International Quality Control Round Assessment

Anna Falk, University of Lund, Sweden
12:00 – 12:45

Keynote Conference: Reverse Genetic Engineering Stem Cell Sources for Safe and Optimized Universal Therapy

Andras Nagy, University of Toronto, Canada

12:45 – 14:00 Lunch & Sponsor Booth Visits

Session IV – Novel iPSC-Derived Cell Therapy Products & Technologies

14:00 – 14:45

Keynote Conference: Chemical Reprogramming and ciPSC-Derived Islets for Diabetes Therapy

Hongkui Deng, Beijing University, China

14:45 – 15:15

Novel ESC based therapeutics for sensorial hearing loss

Marcelo Rivolta, University of Sheffield, UK

15:15 – 16:00

Panel Discussion : Allogeneic versus Autologous iPSCs in clinical applications

Chairman : Glyn Stacey, with H. Deng, A. Nagy, Anna Falk, Ali Turhan, Ana Veiga

16:00 – 16:30 Coffee Break
16:30 – 17:30

iPSC Technology: Differentiation, Maturation and Beyond

Short selected talks
17:30 Closing Remarks

SCIENTIFIC ADVISORY BOARD

The Agenda has been setup by the Scientific Advisory Board composed of the following Experts :

Prof. Annelise Bennaceur Griscelli

Professor Hematology
School of Medicine
Paris Saclay University,
Director of CiTHERA, the Center for iPS Cell Therapies
Coordinator of The National iPSC Infrastructure INGESTEM,
Co-Founder of iPSirius

Prof. Ali Turhan

Professor of Hematology
School of Medicine
Paris Saclay University, France
Director of Clinical iPSC Program at CiTHERA/ INSERM U1210, France
Co-founder iPSirius

Prof. Anna Veiga

Director of the Barcelona Stem Cell Bank
Group leader at Pluripotent Stem Cell Therapy research group at the Regenerative Medicine Program (REGENBELL) at Institut d’ Investigació Biomèdica de Bellvitge (IDIBELL), Spain

Dr. Glyn Stacey

Professor at the Universities of Bedfordshire and Suffolk,UK
Institute of Stem Cell and Regeneration, CAS, Beijing, China

Dr. Anselme L. Perrier

Research Director at INSERM
Group leader at the CEA/CNRS U9199  Laboratory of Neurodegenerative Diseases,MIRCEN Infrastructure, France

Dr. Pierre Savatier

Research Director at INSERM
Stem-cell & Brain Research Institute (SBRI)
National Pluripotent Stem Cell Infrastructure INGESTEM, France